The global iron-deficiency anemia therapy market refers to the dynamic landscape of products and services aimed at addressing the prevalent health issue of insufficient iron levels in the bloodstream. This market encompasses pharmaceuticals, supplements, and medical interventions designed to combat and alleviate iron deficiency anemia; a condition characterized by a lack of red blood cells due to insufficient iron. Ongoing collaborations, advancements in medical technologies, and a focus on improving patient outcomes contribute to the evolving landscape of the global iron-deficiency anemia therapy market.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market
Data Bridge Market Research analyses that the Global Iron-Deficiency Anemia Therapy Market, which is USD 3,710.61 million in 2022, is expected to reach USD 13,208.89 million by 2030, at a CAGR of 17.2% during the forecast period 2023 to 2030. As the global population ages, susceptibility to iron deficiency anemia increases, driving a natural market expansion. The rising prevalence among the elderly fuels the demand for effective therapies, emphasizing the importance of addressing nutritional deficiencies in an aging demographic through targeted healthcare solutions.
Key Findings of the Study
Elevated healthcare expenditure is expected to drive the market's growth rate
Global increases in healthcare spending provide a fertile ground for substantial investments in the research, development, and accessibility of treatments for iron-deficiency anemia. This financial commitment supports the creation of innovative therapeutic solutions, enhances the efficiency of existing interventions, and broadens patient access to these crucial therapies. The rising financial support within the healthcare sector propels market growth, facilitating advancements that address the multifaceted challenges associated with iron-deficiency anemia on a global scale.
Report Scope and Market Segmentation
Report Metric
|
Details
|
Forecast Period
|
2023 to 2030
|
Base Year
|
2022
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
Segments Covered
|
Therapy (Parenteral Iron Therapy, Oral Iron Therapy), Therapy Areas (Inflammatory Bowel Disease, Renal, Obstetrics and Gynecology, Congestive Heart Failure (CHF), Oncology, Others) Population (Adults, Pediatric, Geriatric), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
Market Players Covered
|
Fresenius SE & Co. KGaA (Germany), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Ireland), Lupin (India), ViforPharma Ltd. (Switzerland), AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global iron-deficiency anemia therapy market is segmented on the basis of therapy, therapy areas, population, end-users and distribution channel.
- On the basis of therapy, the global iron-deficiency anemia therapy market is segmented into parenteral iron therapy, and oral iron therapy
- On the basis of therapy areas, the global iron-deficiency anemia therapy market is segmented into inflammatory bowel disease, renal, obstetrics and gynecology, congestive heart failure (chf), oncology, and others
- On the basis of population, the global iron-deficiency anemia therapy market is segmented into adults, pediatric, and geriatric
- On the basis of end-users, the global iron-deficiency anemia therapy market is segmented into hospitals, specialty clinics, homecare, and others
- On the basis of distribution channel, the global iron-deficiency anemia therapy market is segmented into hospital pharmacy, retail pharmacy, online pharmacy, and others
Major Players
Data Bridge Market Research recognizes the following companies as the major global iron-deficiency anemia therapy market players in global iron-deficiency anemia therapy market are AMAG Pharmaceuticals (U.S.), Akebia Therapeutics, INC. (U.S.), CHO-A Pharmaceutical CO., LTD. (South Korea), Orion Corporation (Finland), Pharmacosmos A/S (Denmark), Shield Therapeutics (U.K.), Advanz Pharmaceutical (U.K.), Alkem Labs (India), Zydus Cadila (India), Hikma Pharmaceuticals PLC (U.K.)
Market Developments
- In September 2022, Zydus Lifesciences achieved a significant milestone by acquiring marketing rights for the iron deficiency anemia drug MonoFerric (iron isomaltoside) injection in India and Nepal from Pharmacosmos. This strategic move enhances Zydus Lifesciences' portfolio, allowing them to address the growing health concerns related to iron deficiency in these regions. The acquisition aligns with Zydus Lifesciences' commitment to expanding its pharmaceutical offerings and ensuring broader accessibility to innovative therapies, thereby contributing to improved healthcare outcomes for individuals affected by iron deficiency anemia in India and Nepal.
- In March 2022, a significant milestone was reached in India's healthcare landscape as the Drug Controller General approved Zydus's New Drug Application for Oxemia. Oxemia, an oral, small molecule hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor, received approval for treating anemia linked to chronic kidney disease (CKD). This regulatory nod underscores the drug's efficacy and safety profile. The approval marks a crucial advancement in addressing anemia associated with CKD, providing patients in India with a promising therapeutic option to manage this prevalent and challenging condition
- In 2021, Sandoz marked a significant milestone with the introduction of Ferumoxytol Injection, the inaugural generic high-dose intravenous iron. Specifically designed to address anemia resulting from iron deficiency in U.S. patients, Ferumoxytol proves valuable for adults averse to oral iron, exhibiting poor reactions to it, or suffering from chronic renal disease. This generic alternative mirrors AMAG Pharmaceuticals' Feraheme, offering an accessible and cost-effective solution to a broader demographic
Regional Analysis
Geographically, the countries covered in the global iron-deficiency anemia therapy market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
North America is the dominant region in the global iron-deficiency anemia therapy market during the forecast period 2023-2030
North America dominates the global iron-deficiency anemia therapy market due to the region's advanced healthcare system. The market's growth in this region is further accelerated by key players prioritizing novel technologies. Increased emphasis on technological advancements by industry leaders enhances treatment efficacy, fosters innovation, and contributes to the overall expansion of therapeutic options. This, combined with the robust healthcare infrastructure, positions North America as a frontrunner in shaping the trajectory of iron-deficiency anemia therapies on a global scale.
Asia-Pacific is estimated to be the fastest-growing region in the global iron-deficiency anemia therapy market in the forecast period 2023-2030
Asia-Pacific is expected to dominate the global iron-deficiency anemia therapy market from 2023 to 2030, exhibiting the highest growth rate. This projection is attributed to the region's escalating healthcare costs, a burgeoning population, government initiatives to enhance the healthcare sector, and a surging demand for effective therapies to combat iron-deficiency anemia. The confluence of these factors positions Asia-Pacific as a pivotal player in shaping the trajectory of advancements and market expansion in the forecast period.
For more detailed information about the global iron-deficiency anemia therapy market report, click here – https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market